Two heart drugs, Vytorin and Zetia, have combined for $5 billion in sales but a long-term study has found that they might not work any better than older, cheaper meds.
![]()
![]()
Originally Syndicated via RSS from Wired: Top Stories


Two heart drugs, Vytorin and Zetia, have combined for $5 billion in sales but a long-term study has found that they might not work any better than older, cheaper meds.
![]()
![]()
Originally Syndicated via RSS from Wired: Top Stories